MultiCorp International CEO Paul D. Lisenby noted that the company is extremely excited to have such a qualified and experienced group to assist the company in mapping out a clear strategy for the migraine medication to gain approval from the FDA.
"While we understand this could be a long process, having a group that is so well versed on the proper procedures clinical trials require to gain approval, we feel we’ve chosen the perfect group to accomplish this portion of the process in the most expeditious manner possible. Once the report is completed in the next four to six weeks, the company will have a clear understanding as to the requirements from the FDA on beginning clinical trials.
"We feel this medication could become a major player in the $3.2 billion dollar segment of the migraine pharmaceutical vertical," Lisenby added.